Astro Pak launches decontamination services subsidiary
Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.
SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.
The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.
The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.
Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.
In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
You may also like
Trending Articles
You may also like
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development
Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates
The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development
Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production